Liver Cancer Clinical Trials

1st LINE Therapeutic

**Unresectable**

- **UCI 01-61**
  A Humanitarian device exemption use protocol of TheraSphere for treatment of Unresectable Hepatocellular Carcinoma (Abi-Jaoudeh)

- **UCI 15-80**
  Phase III Comparing Pexa-Vec Followed by Sorafenib vs. Sorafenib Pts w/ HCC w/o Prior Systemic Therapy (Abi-Jaoudeh)

- **UCI 15-81**
  Phase 1 Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Hepatocellular Carcinoma (Abi-Jaoudeh)

- **UCI 16-40**
  An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects with Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma (Imagawa)

**Correlative**

- **UCI 03-03** Immunologic Factors Affecting Outcomes in Patients with Liver Cancer (Imagawa)

2nd LINE Therapeutic

**Unresectable or Metastatic**

- **UCI 16-29**
  Dynamic Contrast Enhanced Magnetic Resonance Imaging as a Biomarker to Predict Response to Liver Tumor Embolization (Lam)

- **UCI 16-81**
  Comparing trans-arterial chemoembolization outcome using cone beam CT vs. conventional fluoroscopy (Abi-Jaoudeh)

- **UCI 16-94**
  Phase IIA Single Arm Study of Treatment of Patients with Advanced Liver Cancer with a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD1 monoclonal antibody (Abi-Jaoudeh)

**ECOG EAY131 (MATCH)**
Molecular Analysis for Therapy Choice (Bota)

**SWOG S1609**
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

**Opening soon**